Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

NCT03932318 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped study postponed

Conditions

Acute Myeloid Leukemia
Relapsed Adult AML

Interventions

BIOLOGICAL: Lintuzumab-Ac225
DRUG: Venetoclax
DRUG: Azacitidine

Sponsor

Actinium Pharmaceuticals